Today: 22 January 2026
Subscribe
Browse Category

Pharmaceuticals News 30 November 2025 - 3 December 2025

Pfizer Stock (PFE) Today – Price, Metsera Obesity Bet, RSV Vaccine Tailwinds and 2026 Forecast (3 December 2025)

Pfizer Stock (PFE) Today – Price, Metsera Obesity Bet, RSV Vaccine Tailwinds and 2026 Forecast (3 December 2025)

Pfizer Inc. (NYSE: PFE) remains one of the most closely watched healthcare stocks as of December 3, 2025. The share price is still stuck near post‑COVID lows, but a new $10 billion obesity‑drug acquisition, expanding RSV vaccine markets and a hefty dividend yield around 6.5–7% are reshaping the narrative around the stock. Pfizer Below is a deep dive into where…
3 December 2025
···
Regeneron Pharmaceuticals (REGN) Stock Outlook: Morgan Stanley Downgrade, Eylea HD Win and Gene‑Editing Push – December 3, 2025Regeneron

Regeneron Pharmaceuticals (REGN) Stock Outlook: Morgan Stanley Downgrade, Eylea HD Win and Gene‑Editing Push – December 3, 2025Regeneron

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is ending 2025 in full “complex biotech” mode: the share price has rebounded, the dividend is now real, a flagship drug just got a powerful new label, a rare-disease medicine crushed a Phase 3 trial, and Wall Street is suddenly a bit less euphoric about the stock. On December 3, Morgan Stanley cut Regeneron from…
3 December 2025
···
Bristol-Myers Squibb (BMY) Stock Today: Celgene Lawsuit Shock, ASH 2025 Momentum and 2026 Forecasts

Bristol-Myers Squibb (BMY) Stock Today: Celgene Lawsuit Shock, ASH 2025 Momentum and 2026 Forecasts

On December 2, 2025, Bristol-Myers Squibb (NYSE: BMY) found itself at the center of two very different storylines: a revived $6.7 billion Celgene lawsuit and strong hematology data at ASH 2025. Together with a hefty dividend and low valuation multiples, these cross-currents are shaping how investors see BMY stock heading into 2026. BMY Stock Snapshot on 2 December 2025 On…
3 December 2025
····
Merck (MRK) Stock on December 2, 2025: Dividend Hike, FDA Wins and Fresh Wall Street Targets

Merck (MRK) Stock on December 2, 2025: Dividend Hike, FDA Wins and Fresh Wall Street Targets

Merck & Co., Inc. (NYSE: MRK) is wrapping up 2025 with a flurry of news that matters to shareholders: a bigger dividend, new analyst price targets, fresh regulatory approvals for its cancer blockbuster Keytruda, and high‑profile acquisitions aimed at life after its 2028 patent cliff. As of early afternoon on December 2, 2025, Merck shares trade around $101 (roughly $100.8–$101.0,…
2 December 2025
····
Johnson & Johnson (JNJ) Stock Near Record Highs: New EU Drug Approval, Oncology Deal and 2026 Outlook

Johnson & Johnson (JNJ) Stock Near Record Highs: New EU Drug Approval, Oncology Deal and 2026 Outlook

As of December 2, 2025, Johnson & Johnson (NYSE: JNJ) is trading just below all‑time highs, supported by a powerful 2025 rally, a fresh European Union drug approval, a new $3.05 billion oncology acquisition, and a planned spin‑off of its orthopaedics business. Together, these moves are reshaping the investment case for JNJ as it heads into 2026. Below is a…
2 December 2025
····
Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

Eli Lilly’s stock is trading just below record highs after a historic run driven by obesity and diabetes drugs. Fresh price cuts, powerful earnings and evolving obesity guidelines are reshaping the outlook as of December 2, 2025. Eli Lilly Stock Today: High Price, High Expectations As of mid‑day on December 2, 2025, Eli Lilly and Company (NYSE: LLY) is trading…
2 December 2025
····
GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK plc (LSE: GSK, NYSE: GSK) heads into the final month of 2025 near multi‑year highs, powered by a strong run of earnings beats, a revived oncology franchise and a looming change at the top of the company. As of 2 December 2025, the stock sits close to its 52‑week peak while analyst opinion remains broadly neutral and focused on…
2 December 2025
··
Bayer Stock Rockets on U.S. Roundup Breakthrough – Is the 13% Rally the Start of a Trend?

Bayer Stock Rockets on U.S. Roundup Breakthrough – Is the 13% Rally the Start of a Trend?

Bayer’s share price is exploding today. On 2 December 2025, the German blue chip (ISIN DE000BAY0017, ticker BAYN) is trading around €34–35 on Xetra, up roughly 13% intraday and at a fresh year high. Finanznachrichten The trigger: a major twist in the U.S. Roundup™ glyphosate litigation – and a renewed wave of analyst upgrades and fresh pipeline news that could reshape the investment story. Below is a…
2 December 2025
····
Wockhardt share price soars 27% in two days after historic US FDA step for Zaynich

Wockhardt share price soars 27% in two days after historic US FDA step for Zaynich

Wockhardt Limited has suddenly jumped back into the market spotlight. On 2 December 2025, the Wockhardt share price extended a powerful breakout rally triggered by a landmark US regulatory milestone for its novel antibiotic Zaynich, making the stock one of the most-watched names in India’s pharma space this week. NDTV Profit Below is a deep dive into the latest news,…
2 December 2025
···
AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

AbbVie Inc. (NYSE: ABBV) heads into December 2025 as one of the world’s largest healthcare companies, with new migraine data, fresh oncology approvals, a raised 2025 profit forecast and looming U.S. drug‑pricing reforms all shaping sentiment around the stock. The Motley Fool Below is a detailed look at where AbbVie’s stock stands today, what has changed since late November, and…
1 December 2025
····
GSK Stock on 1 December 2025: Big 2025 Rally, Blenrep’s Comeback and a New CEO – What Investors Need to Know Now

GSK Stock on 1 December 2025: Big 2025 Rally, Blenrep’s Comeback and a New CEO – What Investors Need to Know Now

GSK plc (NYSE: GSK) heads into December 2025 as one of the stronger-performing big pharma names, with the share price hovering just below a 52‑week high after a year of earnings beats, upgraded guidance, revived cancer assets and a looming CEO handover. The U.S. ADR last traded at about $47.9 (close on 28 November), with a 52‑week range of roughly…
1 December 2025
···
Pfizer (PFE) Stock Outlook Before the December 1, 2025 Open: Price, Metsera Obesity Deal, Dividend Payout and Wall Street Forecasts

Pfizer (PFE) Stock Outlook Before the December 1, 2025 Open: Price, Metsera Obesity Deal, Dividend Payout and Wall Street Forecasts

As U.S. markets prepare to reopen on Monday, December 1, 2025, Pfizer Inc. (NYSE: PFE) heads into the new week trading in a tight range but surrounded by a flurry of fresh analysis, institutional activity and strategic news from November 28–30. At the close on Friday, November 28, 2025, Pfizer shares finished around $25.74, giving the drugmaker a market capitalization…
30 November 2025
····
1 … 31 32 33 34 35 … 46

Stock Market Today

  • Palantir Poised for Profit Growth Amid AI Market Caution
    January 22, 2026, 2:14 PM EST. Palantir Technologies (PLTR) shows strong revenue and profit growth, with Q3 revenue up 63% year-over-year to $1.18 billion and operating income more than tripling, reflecting its scalable AI software business model. Despite being valued at over 200 times 2025's expected profits, analysts expect earnings to rise from $0.72 in 2025 to $2.21 by 2029, indicating accelerating profitability. However, the stock trades at a premium with a 112 times trailing sales and 172 times projected 2026 earnings multiple, raising questions about its near-term valuation. Market skepticism about an AI bubble weighs on investor sentiment, but Palantir's solid fundamentals and enterprise customer base position it as a potential 2026 market surprise.
Go toTop